<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Bone marrow mesenchymal stroma cells (BMSC) are key components of the hematopoietic microenvironment </plain></SENT>
<SENT sid="1" pm="."><plain>The question of whether BMSC from patients with <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> have cytogenetic abnormalities is discussed controversially, some studies indicating that they are cytogenetically <z:mpath ids='MPATH_458'>normal</z:mpath> and others providing evidence of their aberrations </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: We performed standard and molecular cytogenetic analyses of both hematopoietic cells and BMSC from 31 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, n = 18) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, n = 13) and 7 healthy individuals </plain></SENT>
<SENT sid="3" pm="."><plain>Mononuclear cells were isolated from fresh bone marrow aspirates at the time of initial diagnosis for cytogenetic analysis of hematopoietic cells (HC) and selection of BMSC </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Clonal cytogenetic aberrations were observed in HC from 8 (44%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 8 (61%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="5" pm="."><plain>Cytogenetic analyses of BMSC were successfully performed in 27 of the 31 cases </plain></SENT>
<SENT sid="6" pm="."><plain>Structural chromosomal aberrations, including t(1;7), t(4;7), t(7;9), t(7;10), t(7;19), t(15;17), and others, were detectable in BMSC from 7 of 16 (44%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 6 of 11 (54%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="7" pm="."><plain>The breakpoints of chromosomes in BMSC were typical for <z:hpo ids='HP_0001909'>leukemia</z:hpo> aberrations </plain></SENT>
<SENT sid="8" pm="."><plain>Two patients showed clonal chromosomal markers </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: BMSC from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients show chromosomal abnormalities </plain></SENT>
<SENT sid="10" pm="."><plain>Although the majority of cytogenetic aberrations in BMSC were not clonal and differed from chromosomal markers in HC from the same individual, detection of typical chromosomal changes in BMSC suggests enhanced genetic susceptibility of these cells in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>This may indicate potential involvement of BMSC in the pathophysiology of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>